Autologous bone

Thierry P, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplant as compared with salvage chemotherapy in relapses... 

Leukine Sargramostim (GM-CSF) Immunex Autologous bone marrow transplantation, neutropenia resulting from chemotherapy, peripheral blood progenitor cell mobilization, and transplantation... 

Leukine (sargramostim, GM-CSF) Autologous bone marrow transplantation Neutrophil recovery after bone marrow transplantation Berlex Labs... 

G-CSF and GM-CSF have also found application after allogenic or autologous bone marrow transplantation, to accelerate neutrophil recovery. (Allogenic means that donor and recipient are different individuals, and autologous means that donor and recipient are the same.)... 

Autologous bone marrow transplant Neutropenia resulting from chemotherapy Allogeneic bone marrow transplant Peripheral blood progenitor cell mobilization Leukemias (leukopenias and fungal infection) March 1991 Sept. 1995 Nov. 1995 Dec. 1995 Nov. 1996... 

Brandt, S J. et al., Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation, N. Engl. J Med, 318, 869, 1988. 

Shintani, S., Murohara, T., Ikeda, H., Ueno, T., Sasaki, K, Duan, J. and Imaizumi, T. (2001) Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 103, 897-903. 

S-HT 5-hydroxytryptamine AA African American AB abortion Ab antibody abd abdomen/abdominal ABMT autologous bone marrow transplantation Abs antibodies... 

Adult bone marrow-derived stem cells are presently the cell types most widely utilized in cardiac stem cell therapy. A heterogeneous subset, termed autologous bone marrow-derived mononuclear cells (ABMMNCs), is composed of small amounts of stromal or MSCs, HPCs, EPCs, and more committed cell lineages, such as natural killer lymphocytes, T lymphocytes, B lymphocytes, and others [2]. 

Outside the AMI setting, stem cells have been used to treat patients with ischemic heart disease with or without systolic functional compromise and patients unsuitable for myocardial revascularization (Tables 7.3 and 7.4). Autologous bone marrow stem cells have been used to treat patients with chronic myocardial ischemia, including ischemic heart failure with or without systolic functional compromise, and patients ineligible for myocardial revascularization (Table 7.4). The preliminary clinical evidence supports the efficacy of this new therapy and, at this point, all the evidence appears to substantiate its safety. 

Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, LinS, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004 94 92-95. 

B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronaiy autologous bone-marrow cell transfer after myocardial infarction the BOOST randomised controlled clinical trial. Lancet 2004 364 141-148. 

Hamano K, Nishida M, Hirata K, Mikamo A, Li TS, Harada M, Miura T, Matsuzaki M, Esato K. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease clinical trial and preliminary results. Jpn Circ / 2001 65 845-847. 

Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schumichen C, Nienaber CA, Freund M, Steinhoff G. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003 361 45 6. 

Fuchs S, Baffour R, Zhou YF, Shou M, Pierre A, Tio FO, Weissman NJ, Leon MB, Epstein SB, Kornowski R. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. JAm Coll Cardw/2001 37 1726-1732. 

Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003 361 47-A9. 

Dohmann HF, Perin EC, Takiya CM, Silva GV, Silva SA, Sousa AL, Mesquita CT, Rossi MI, Pascarelli BM, Assis IM, Dutra HS, Assad JA, Castello-Branco RV, Drummond C, Dohmann HJ, Willerson JT, Borojevic R. Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure postmortem anatomicopathologic and immunohistochemical findings. Circulation 2005 112 521-526. 

Fuchs S, Satler LF, Kornowski R, Okubagzi P, Weisz G, Baffour R, Waksman R, Weissman NJ, Cerqueira M, Leon MB, Epstein SE. Catheter-based autologous bone marrow myocardial injection in nooption patients with advanced coronary artery disease a feasibility study. J Am Coll Cardiol 2003 41 1721-1724. 

Perin EC, Dohmann HE, Borojevic R, et al. Transendo-cardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. May 13 2003 107(18) 2294-2302. 

Autologous bone marrow transplantation involves initial removal of some marrow from the patient, its storage in liquid nitrogen, followed by its re-introduction into the patient subsequent to chemo- or radiotherapy. Leukine is the tradename given to a recombinant human GM-CSF preparation produced in engineered S. cerevisiae (Table 6.4). 

Nevertheless, immunotoxins may be useful for purging cancer cells in bone marrow aspirate isolated from patients undergoing autologous bone marrow transplantation [29,30]. When no suitable bone marrow donor is available, the patients own marrow cells are collected for repopulation of immune cells after radiation and chemotherapy. The small fraction of leukemic cells in autologous bone marrow cells can be removed with immunotoxins before they are reintroduced to the patient for restoring their immune system. Because this procedure... 

High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors McGuire, W.P. (1998). Curr Probl Cancer, 22 (3) 135-77. 

---